Business Context and Reporting Period
Company: Pavmed Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 2, 2021
Reporting Period: Event date March 2, 2021
Pavmed Inc., an emerging growth company incorporated in Delaware, reported the termination of a material definitive agreement involving the full repayment of its outstanding convertible debt.
Key Financial Metrics
Debt Repayment: $14,466,250
Outstanding Convertible Debt Post-Event: $0 (All obligations satisfied)
Revenue, Profit, Cash Flow, Margins, Liquidity: The filing text does not provide a clear value for these metrics.
Material Changes
- Debt Elimination: The Company repaid in full all outstanding convertible notes held by Alto Opportunity Master Fund, SPC-Segregated Master Portfolio B ("Alto B").
- Agreement Termination: Upon repayment, all obligations under the Securities Purchase Agreements dated April 30, 2020, and August 5, 2020, were deemed satisfied.
Outlook, Risks, and Management Commentary
Management Commentary: The filing confirms the successful settlement of the Company's entire convertible debt portfolio. No forward-looking guidance, risk factors, or contingencies are detailed in this specific 8-K report.
Investor Verification Checklist
- Verify the source of funds used to repay the $14,466,250 debt obligation.
- Confirm the impact of this repayment on the Company's current cash position and liquidity.
- Review the attached press release (Exhibit 99.1) for additional context on the transaction.
- Check subsequent filings for any new debt issuances or changes in capital structure.